TP1 GUIDELINE-CONCORDANT TREATMENT AND ITS IMPACT ON SURVIVAL AND COSTS AMONG ELDERLY WOMEN WITH HER2-NEGATIVE METASTATIC BREAST CANCER.

There is scarce data on the effect of concordance to the National Comprehensive Cancer Network (NCCN) treatment guidelines on clinical and economic outcomes among patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). The objective of this study was to examine the effect of guideline-concordant treatment among elderly women with HER2-negative MBC on all-cause mortality, breast cancer-specific mortality, and Medicare costs. In adjusted analyses, we found that women who did not receive guideline-concordant treatment had significantly higher hazards of all-cause mortality (hazard ratio (HR)=2.143, p<0.001) and breast cancer-specific mortality (HR=1.989, p<0.001) than those who received guideline-concordant treatment. [Extracted from the article]